



Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION



FDA ADVISORY
No. 2017-063-A

17 MAR 2021

TO: THE GENERAL PUBLIC

SUBJECT: Lifting the Advisory on the Notified Cosmetic Product "ASHLEY SHINE BABE SKIN PROFESSIONAL SILK-ENRICHED SHINE REDUCTION POWDER (AS8029)" under FDA Advisory No. 2017-063 "Public Health Warning Against the Purchase and Use of Unnotified Cosmetic Products (Batch 20)" Dated 28 February 2017

The Food and Drug Administration (FDA) informs the public that the Cosmetic product **Ashley Shine Babe Skin Professional Silk-Enriched Shine Reduction Powder (AS8029)** with **Notification No. 1000005739153**, has been notified by the Market Authorization Holder, Elegant Fumes Beauty Products, Inc., in accordance with existing FDA rules and regulations.

Accordingly, the warning against the purchase and use of the subject product as mentioned in FDA Advisory No. 2017-063 and its corresponding FDA Order is hereby lifted.


The public is advised to always check if a Cosmetic product is notified with the FDA by using the FDA Verification Portal feature accessible at <https://verification.fda.gov.ph> which may be used by typing in the name of the product before purchasing. For more information or inquiries, please email us at ecchuhsrr_prsdd@fda.gov.ph. You may also call the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research at telephone number **(02) 8857-1900 loc. 8113 or 8117**.

To report the sale or distribution of any unnotified/unregistered health products, kindly email FDA via ereport@fda.gov.ph.

The public health warning imposed on the remaining products listed in FDA Advisory No. 2017-063 shall remain to be upheld and shall not be affected by the issuance of this advisory.

Furthermore, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to the existing laws, rules, and regulations.

Dissemination of this advisory to all concerned is hereby requested.


ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN 20210311140332

